Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Unspecified Adult Solid Tumor, Protocol Specific: early-phase trial registry
5 of 112 indexed Unspecified Adult Solid Tumor, Protocol Specific trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #115 of 28,707 conditions by registered trial count.
112 US clinical trials · 5 currently recruiting · #115 of 28,707 conditions by registered trial count
Unspecified Adult Solid Tumor, Protocol Specific: 112 US clinical trials tracked, 5 recruiting.
Unspecified Adult Solid Tumor, Protocol Specific is the subject of 112 registered US clinical trials on ClinicalTrials.gov, 5 of them currently open to new participants. 10 are in Phase 3-4 (later-stage) and 93 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 26 of these trials.
Enrollment posture brief
Registry condition unspecified-adult-solid-tumor-protocol-specific
OPEN 5 | RECR 4% | LATE 10 | EARLY 93 | RANK #115 | SPON 26
Volume-matched condition peers
Nearest open-share peer: Attention Deficit Disorder With Hyperactivity (5% recruiting · 21 trials)
Unspecified Adult Solid Tumor, Protocol Specific lists 5 open slots (4% of 112 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Unspecified Adult Solid Tumor, Protocol Specific on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Unspecified Adult Solid Tumor, Protocol Specific is recruiting below its size-band peers.
5 of 112 indexed trials (4.5%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Unspecified Adult Solid Tumor, Protocol Specific research.
National Cancer Institute (NCI) accounts for 26 of 112 trials (23.2%). 46 distinct sponsors appear on at least one study for this condition label.
-
Most Unspecified Adult Solid Tumor, Protocol Specific trials plan to enrol fewer than 100 people.
Median target enrolment is 40 among the 84 trials that report a genuine target (sentinel values excluded). 66 of those (78.6%) plan for fewer than 100 participants.
-
Unspecified Adult Solid Tumor, Protocol Specific research is mostly interventional.
107 interventional and 5 observational studies make up this index (95.5% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
112 total, page 1 of 3
Collection and Storage of Tissue Samples From Patients Undergoing Surgery For Suspected Solid Tumors
Wake Forest University Health Sciences
NCT00900471
Collecting Tissue Samples From Patients With Cancer Undergoing Radiation Therapy and Healthy Participants
University of Texas Southwestern Medical Center
NCT00992303
Registry of Older Patients With Cancer
UNC Lineberger Comprehensive Cancer Center
NCT01137825
Genomic Profiling in Recommending Treatment for Patients With Metastatic Solid Tumors
Stanford University
NCT02215928
3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
Barbara Ann Karmanos Cancer Institute
NCT00935090
Assessment Tool for Older Patients With Cancer
City of Hope Medical Center
NCT00477958
RNR Inhibitor COH29 in Treating Patients With Solid Tumors That Are Refractory to Standard Therapy or For Which No Standard Therapy Exists
City of Hope Medical Center
NCT02112565
APF530 or Aloxi (Palonosetron Hydrochloride) Combined With Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Cancer
Heron Therapeutics
NCT00343460
Zoledronate in Treating Patients With Solid Tumors That Have Spread to the Bone
Novartis
NCT00003884
Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer
Mayo Clinic
NCT00661999
Comparison of Nutritional Supplements in Preventing Weight Loss in Patients With Cancer
Radiation Therapy Oncology Group
NCT00053053
Levocarnitine in Treating Fatigue in Cancer Patients
ECOG-ACRIN Cancer Research Group
NCT00091169
Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer
Roswell Park Cancer Institute
NCT00003816
Duloxetine in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer
Alliance for Clinical Trials in Oncology
NCT00489411
(Valerian) for Improving Sleep in Patients With Cancer Receiving Adjuvant Therapy
Alliance for Clinical Trials in Oncology
NCT00075842
Cognitive Behavioral Therapy With or Without Armodafinil in Treating Cancer Survivors With Insomnia and Fatigue After Chemotherapy
Abramson Cancer Center at Penn Medicine
NCT01019187
Methylphenidate in Treating Patients With Fatigue Caused by Cancer
Alliance for Clinical Trials in Oncology
NCT00376675
Irinotecan in Treating Aging Patients With Solid Tumors
Alliance for Clinical Trials in Oncology
NCT00026195
White Wine or Nutritional Supplement in Improving Appetite in Patients With Cancer
Academic and Community Cancer Research United
NCT00936728
Docetaxel in Treating Patients With Solid Tumors
Alliance for Clinical Trials in Oncology
NCT00003565
PS-341 and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors
National Cancer Institute (NCI)
NCT00028587
Assessing Older Patients With Cancer
Alliance for Clinical Trials in Oncology
NCT00416481
Combination Chemotherapy in Treating Patients With Metastatic or Unresectable Solid Tumors
National Cancer Institute (NCI)
NCT00058253
Tanespimycin, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Advanced Solid Tumors
National Cancer Institute (NCI)
NCT00047047
Combination Chemotherapy in Treating Patients With Refractory or Recurrent Solid Tumors
Memorial Sloan Kettering Cancer Center
NCT00003004
Fludeoxyglucose F 18 PET/CT Imaging in Finding Cancer in Patients Undergoing Surgery for Solid Tumors
Ohio State University Comprehensive Cancer Center
NCT00816335
Erlotinib and Cetuximab in Treating Patients With Advanced Solid Tumors With Emphasis on Non-Small Cell Lung Cancer
University of California, Davis
NCT00408499
2-Methoxyestradiol in Treating Patients With Advanced Solid Tumors
National Cancer Institute (NCI)
NCT00028821
Docetaxel, Oxaliplatin, and Fluorouracil in Treating Patients With Metastatic or Unresectable Stomach Cancer, Gastroesophageal Junction Cancer, or Other Solid Tumor
Northwestern University
NCT00711243
Suberoylanilide Hydroxamic Acid, Fluorouracil, Leucovorin, and Oxaliplatin in Treating Patients With Progressive Metastatic or Unresectable Colorectal Cancer or Other Solid Tumors
National Cancer Institute (NCI)
NCT00138177
Bortezomib and Topotecan Hydrochloride in Treating Patients With Advanced Solid Tumors
City of Hope Medical Center
NCT00541359
1-Methyl-D-Tryptophan in Treating Patients With Metastatic or Refractory Solid Tumors That Cannot Be Removed By Surgery
National Cancer Institute (NCI)
NCT00567931
EF5 in Treating Patients With Solid Tumors
National Cancer Institute (NCI)
NCT00003282
LY231514 in Treating Patients With Locally Advanced or Metastatic Solid Tumors and Varying Degrees of Kidney Function
The University of Texas Health Science Center at San Antonio
NCT00003706
Sorafenib and Bortezomib in Treating Patients With Advanced Cancer
National Cancer Institute (NCI)
NCT00303797
Docetaxel and Irinotecan in Treating Patients With Advanced Solid Tumors
Yale University
NCT00004923
Bortezomib and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors
National Cancer Institute (NCI)
NCT00030368
Calcitriol Plus Paclitaxel in Treating Patients With Advanced Solid Tumors
University of Pittsburgh
NCT00009802
S0916, MLN1202 in Treating Patients With Bone Metastases
SWOG Cancer Research Network
NCT01015560
Combination Therapy With Oral 9-Nitrocamptothecin & Oral Etoposide
H. Lee Moffitt Cancer Center and Research Institute
NCT00006047
PI-88 in Treating Patients With an Advanced Malignancy (Cancer) or Stage IV Melanoma
Cellxpert Biotechnology
NCT00073892
Tirapazamine, Carboplatin, and Paclitaxel in Treating Patients With Advanced Malignant Solid Tumors
City of Hope Medical Center
NCT00005078
Safingol and Cisplatin in Treating Patients With Locally Advanced or Metastatic Solid Tumors
Memorial Sloan Kettering Cancer Center
NCT00084812
L-778,123 in Treating Patients With Recurrent or Refractory Solid Tumors
Memorial Sloan Kettering Cancer Center
NCT00003430
Imatinib Mesylate and Bevacizumab in Treating Patients With Advanced Melanoma or Other Advanced Cancers
National Cancer Institute (NCI)
NCT00074308
Sorafenib and Temsirolimus in Treating Patients With Unresectable or Metastatic Solid Tumors
National Cancer Institute (NCI)
NCT00255658
UMCC 2003-064 Resveratrol in Preventing Cancer in Healthy Participants
National Cancer Institute (NCI)
NCT00098969
GTI-2040 and Gemcitabine in Treating Patients With Metastatic or Unresectable Solid Tumors
National Cancer Institute (NCI)
NCT00078962
Ro 31-7453 in Treating Patients With Locally Advanced or Metastatic Solid Tumor
Memorial Sloan Kettering Cancer Center
NCT00003755
Hydroxychloroquine and Temozolomide in Treating Patients With Metastatic or Unresectable Solid Tumors
Abramson Cancer Center at Penn Medicine
NCT00714181
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 85 |
| Phase 2 | 8 |
| Phase 3 | 10 |
Top Sponsors
Named interventions
Most-linked intervention names on Unspecified Adult Solid Tumor, Protocol Specific records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Unspecified Adult Solid Tumor, Protocol Specific trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Unspecified Adult Solid Tumor, Protocol Specific page
112 registered trials, 5 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 5 Unspecified Adult Solid Tumor, Protocol Specific trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Cancer Institute (NCI) sponsors the most Unspecified Adult Solid Tumor, Protocol Specific trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Unspecified Adult Solid Tumor, Protocol Specific condition card totals 112 registered trials; most-linked intervention laboratory biomarker analysis; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.